300142 沃森生物
已收盘 02-27 15:00:00
资讯
新帖
简况
沃森生物：公司与相关方共同发起设立云南创沃生物产业投资基金
证券之星 · 02-27 16:48
沃森生物：公司与相关方共同发起设立云南创沃生物产业投资基金
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 02-27 16:42
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物：目前为天然藻源
证券之星 · 02-26 15:07
沃森生物：目前为天然藻源
沃森生物：公司20价肺炎球菌多糖结合疫苗目前处于I期临床试验的准备阶段
证券之星 · 02-12
沃森生物：公司20价肺炎球菌多糖结合疫苗目前处于I期临床试验的准备阶段
沃森生物：公司将严格按照相关法律法规和药监部门的相关规定进行分类
证券之星 · 02-12
沃森生物：公司将严格按照相关法律法规和药监部门的相关规定进行分类
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
21世纪经济报道 · 02-12
新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎
沃森生物(300142.SZ)拟出资4.5亿元发起设立云南创沃生物产业投资基金
智通财经 · 02-11
沃森生物(300142.SZ)拟出资4.5亿元发起设立云南创沃生物产业投资基金
沃森生物最新公告：公司水痘减毒活疫苗获临床试验批准
证券之星 · 02-10
沃森生物最新公告：公司水痘减毒活疫苗获临床试验批准
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 02-10
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
沃森生物：采用13%税率的一般计税政策后，短期会导致公司实际税负有所上升
证券之星 · 02-10
沃森生物：采用13%税率的一般计税政策后，短期会导致公司实际税负有所上升
沃森生物：不断优化核心自主产品的生产和销售工作
证券之星 · 02-05
沃森生物：不断优化核心自主产品的生产和销售工作
股市必读：沃森生物（300142）2月2日董秘有最新回复
证券之星 · 02-03
股市必读：沃森生物（300142）2月2日董秘有最新回复
股市必读：沃森生物（300142）1月29日董秘有最新回复
证券之星 · 01-30
股市必读：沃森生物（300142）1月29日董秘有最新回复
沃森生物：公司上述已上市的疫苗产品中没有流感疫苗
证券之星 · 01-29
沃森生物：公司上述已上市的疫苗产品中没有流感疫苗
沃森生物：已借助AI技术支持研发业务
中金财经 · 01-20
沃森生物：已借助AI技术支持研发业务
沃森生物（300142）披露董事会秘书正式履职公告，1月19日股价下跌1.32%
证券之星 · 01-19
沃森生物（300142）披露董事会秘书正式履职公告，1月19日股价下跌1.32%
沃森生物（300142）披露关于云南证监局责令改正措施的整改报告，1月16日股价下跌3.35%
证券之星 · 01-16
沃森生物（300142）披露关于云南证监局责令改正措施的整改报告，1月16日股价下跌3.35%
沃森生物（300142）披露拟换届董事会人选，1月8日股价上涨1.33%
证券之星 · 01-08
沃森生物（300142）披露拟换届董事会人选，1月8日股价上涨1.33%
每周股票复盘：沃森生物（300142）拟每10股派0.30元现金
证券之星 · 01-03
每周股票复盘：沃森生物（300142）拟每10股派0.30元现金
沃森生物（300142）披露2025年半年度权益分派实施公告，12月31日股价下跌1.45%
证券之星 · 2025-12-31
沃森生物（300142）披露2025年半年度权益分派实施公告，12月31日股价下跌1.45%
加载更多
公司概况
公司名称：
云南沃森生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2010-11-12
主营业务：
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是人用疫苗。
发行价格：
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":12.36,"timestamp":1772175801000,"preClose":12.21,"halted":0,"volume":21990402,"delay":0,"changeRate":0.0123,"floatShares":1556000000,"shares":1599000000,"eps":0.0308,"marketStatus":"已收盘","change":0.15,"latestTime":"02-27 15:00:00","open":12.2,"high":12.36,"low":12.15,"amount":270000000,"amplitude":0.0172,"askPrice":12.36,"askSize":1648,"bidPrice":12.35,"bidSize":415,"shortable":0,"etf":0,"ttmEps":0.0308,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":12.21,"symbolType":"stock","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":13.43,"lowLimit":10.99,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":2.02,"roa":"--","peRate":401.298701,"roe":"1.72%","epsLYR":0.0889,"committee":-0.201501,"marketValue":19768000000,"turnoverRate":0.0141,"status":0,"floatMarketCap":19231000000},"requestUrl":"/m/hq/s/300142","defaultTab":"news","newsList":[{"id":"2614838136","title":"沃森生物：公司与相关方共同发起设立云南创沃生物产业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2614838136","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614838136?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:48","pubTimestamp":1772182101,"startTime":"0","endTime":"0","summary":"公司于2026年2月10日召开第六届董事会第二次会议，审议通过了公司与相关方共同发起设立云南创沃生物产业投资基金，基金目标规模为10亿元，其中，公司以自有资金出资4.5亿元，为有限合伙人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700027008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0239","BK0046","BK0077","BK0070"],"gpt_icon":0},{"id":"2614171838","title":"沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2614171838","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614171838?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:42","pubTimestamp":1772181724,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)02月27日在投资者关系平台上答复投资者关心的问题。投资者提问：九价 HPV 疫苗 Ⅲ 期临床是否已完成全部病例随访？若已完成，总结报告预计何时出具？申报 NDA 的时间窗口是否在 2026 年 Q2？申报前是否需补充临床数据沃森生物回复：尊敬的投资者，您好！公司九价HPV疫苗目前处于III期临床研究阶段，公司在研疫苗的研发若有实质性和阶段性进展公司会及时披露，后续进展情况请关注公司披露的相关信息。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700026805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300142","159646","BK0046","BK0077"],"gpt_icon":0},{"id":"2614094706","title":"沃森生物：目前为天然藻源","url":"https://stock-news.laohu8.com/highlight/detail?id=2614094706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614094706?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:07","pubTimestamp":1772089633,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司旗下爱森泽生物的虾青素，是天然藻源还是化学合成？技术路线是什么？当前虾青素原料市场涨价明显，公司是否有提价计划、产能规划及成本控制措施？谢谢。沃森生物回复：尊敬的投资者，您好！目前为天然藻源。关于相关产品和项目的后续情况请持续关注公司披露的信息。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600016803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300142","BK0070","BK0077"],"gpt_icon":0},{"id":"2610992817","title":"沃森生物：公司20价肺炎球菌多糖结合疫苗目前处于I期临床试验的准备阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992817","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610992817?lang=zh_cn&edition=full","pubTime":"2026-02-12 11:35","pubTimestamp":1770867309,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物02月11日在投资者关系平台上答复投资者关心的问题。mRNA 管线：公司 mRNA 带状疱疹、RSV 疫苗已获临床批件，目前临床 I/II 期进展是否超预期？预计何时进入关键临床阶段？公司20价肺炎球菌多糖结合疫苗目前处于I期临床试验的准备阶段，将按照国家对于注册临床试验的有关程序和要求积极推进。关于20价肺炎结合疫苗的保护效力须以效力临床试验的最终结果为准，请持续关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200014477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0077","BK0046","300142","BK0239","BK0070"],"gpt_icon":0},{"id":"2610992844","title":"沃森生物：公司将严格按照相关法律法规和药监部门的相关规定进行分类","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610992844?lang=zh_cn&edition=full","pubTime":"2026-02-12 11:34","pubTimestamp":1770867286,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物02月11日在投资者关系平台上答复投资者关心的问题。投资者提问：玉溪沃森的2025年公司接受各级管辖部门检查和处罚情况还是没有更新，请问下何时进行更新？？沃森生物官网上双价HPV还列入到非免疫规划里面去了。。关于免疫规划疫苗和非免疫规划疫苗的划分，公司将严格按照相关法律法规和药监部门的相关规定进行分类，感谢您对公司提出的宝贵意见和建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200014443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0070","BK0077","300142"],"gpt_icon":0},{"id":"2610960339","title":"新版基药目录管理办法公布；“减肥神药”或能改善骨关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960339","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610960339?lang=zh_cn&edition=full","pubTime":"2026-02-12 07:27","pubTimestamp":1770852424,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委等11部门联合印发《国家基本药物目录管理办法》2月11日，国家卫生健康委等联合印发《国家基本药物目录管理办法》。与原有的文件相比，《国家基本药物目录管理办法》主要修订六个方面：一是增加法律政策依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602123648366353.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602123648366353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0060","LU1146622755.USD","600276","LU1655091616.SGD","LU1969619763.USD","LU1580142542.USD","LU1997244956.HKD","601607","LU1064130708.USD","301075","BK0183","LU1328615791.USD","BK0209","300683","LU1781817850.SGD","LU0405327148.USD","LU2097828714.EUR","300142","LU2097828805.USD","BK0028","BK0184","LU1064131003.USD","LU2097828557.USD","BK0070","LU2148510915.USD","LU2289578879.USD","BK0188","BK0077","LU1997245177.USD","LU1997245094.SGD","BK0046","BK0097","LU2097828474.EUR","LU1255011170.USD","LU2580892862.HKD","LU2097828631.EUR","LU2580892789.USD","LU2488822045.USD","BK0239","LU0405327494.USD","BK0012","BK0187","LU2328871848.SGD","LU2495084118.USD","BK0020","BK0099","BK0196","LU1820825898.SGD"],"gpt_icon":0},{"id":"2610987141","title":"沃森生物(300142.SZ)拟出资4.5亿元发起设立云南创沃生物产业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2610987141","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610987141?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:05","pubTimestamp":1770800708,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物 发布公告，2026年2月10日，公司召开第六届董事会第二次会议，审议通过了《关于与专业投资机构共同投资并签署<云南创沃生物产业投资基金合伙企业合伙协议>的议案》。根据协议约定，云南创沃生物产业投资基金核心投资方向聚焦合成生物学、生物制造及生物技术相关产业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0239","BK0077","300142","BK0070"],"gpt_icon":0},{"id":"2610364643","title":"沃森生物最新公告：公司水痘减毒活疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2610364643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610364643?lang=zh_cn&edition=full","pubTime":"2026-02-10 18:40","pubTimestamp":1770720036,"startTime":"0","endTime":"0","summary":"沃森生物(300142.SZ)公告称，公司及子公司联合研发的水痘减毒活疫苗获国家药品监督管理局签发的《药物临床试验批准通知书》。该疫苗采用水痘-带状疱疹病毒减毒株接种人二倍体细胞制成，用于预防水痘。目前国内已有六家企业的水痘减毒活疫苗获批上市许可。该疫苗获批进入临床试验，对公司本年度业绩不会产生大的影响，后续还需进行确证性III期临床试验并申请药品上市许可，期间存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000032255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","BK0239","BK0077","BK0046"],"gpt_icon":0},{"id":"2610619862","title":"沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2610619862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610619862?lang=zh_cn&edition=full","pubTime":"2026-02-10 15:06","pubTimestamp":1770707181,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)02月09日在投资者关系平台上答复投资者关心的问题。投资者提问：公司九价HPV疫苗目前III期临床、数据统计、申报准备的最新节点是否顺利？预计提交上市申请的时间窗口与后续规划如何？相比同类产品的临床优势、产能规划、市场定位有哪些积极亮点？沃森生物回复：尊敬的投资者，您好！公司九价HPV疫苗目前处于III期临床研究阶段，公司在研疫苗的研发若有实质性和阶段性进展公司会及时披露，后续进展情况请关注公司披露的相关信息。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000019026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0046","BK0239","BK0077","BK0070","300142"],"gpt_icon":0},{"id":"2610619314","title":"沃森生物：采用13%税率的一般计税政策后，短期会导致公司实际税负有所上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2610619314","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610619314?lang=zh_cn&edition=full","pubTime":"2026-02-10 15:06","pubTimestamp":1770707181,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)02月09日在投资者关系平台上答复投资者关心的问题。投资者提问：增值税取消生物制品3%简易计税，统一按13%一般计税，对贵公司有何影响？沃森生物回复：尊敬的投资者，您好！采用13%税率的一般计税政策后，短期会导致公司实际税负有所上升，但公司产业链条完善，本次调整后，公司将积极梳理供应商情况，进一步优化供应商选择和采购管理，按照新的税务政策缴纳增值税，更加努力做好各项经营管理工作，为公司和股东创造价值。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000019028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0239","BK0046","BK0077","BK0070"],"gpt_icon":0},{"id":"2609344108","title":"沃森生物：不断优化核心自主产品的生产和销售工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2609344108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609344108?lang=zh_cn&edition=full","pubTime":"2026-02-05 11:36","pubTimestamp":1770262583,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)02月04日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司如何在当前医药下行周期调整公司的方向，稳定股价和营业收入呢，可有相应的措施！沃森生物回复：尊敬的投资者，您好！公司将不断优化核心自主产品的生产和销售工作，坚持产品质量不松懈，不断深耕国内市场，持续拓展国际市场。同时，公司还将充分发挥既有研发、产业化能力和优势，拓展新的业务领域和产品管线，集中资源推进新项目落地，为公司和股东创造价值。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500015103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0046","BK0239","300142"],"gpt_icon":0},{"id":"2608899501","title":"股市必读：沃森生物（300142）2月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2608899501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608899501?lang=zh_cn&edition=full","pubTime":"2026-02-03 01:29","pubTimestamp":1770053351,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，沃森生物报收于12.26元，下跌2.93%，换手率2.96%，成交量46.03万手，成交额5.73亿元。董秘最新回复投资者： 请问截止到2026年1月26日，最新股东人数是多少？公司按照相关法规和规范性文件的规定在各期定期报告中披露报告期末的股东人数。当日关注点来自交易信息汇总：2月2日主力资金净流出1647.24万元，显示主力短期减持动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300000965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0070","BK0077","300142","BK0239"],"gpt_icon":0},{"id":"2607377370","title":"股市必读：沃森生物（300142）1月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2607377370","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607377370?lang=zh_cn&edition=full","pubTime":"2026-01-30 01:50","pubTimestamp":1769709021,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，沃森生物报收于12.89元，下跌1.15%，换手率4.5%，成交量70.03万手，成交额9.08亿元。来自公司公告汇总：沃森生物预计2025年度净利润同比增长13.00%至34.00%，但扣除非经常性损益后净利润同比下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000001060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0077","BK0070","300142"],"gpt_icon":0},{"id":"2607727554","title":"沃森生物：公司上述已上市的疫苗产品中没有流感疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2607727554","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607727554?lang=zh_cn&edition=full","pubTime":"2026-01-29 08:54","pubTimestamp":1769648050,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物01月28日在投资者关系平台上答复投资者关心的问题。目前公司共有8个自主疫苗产品正式上市销售，包括：13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗和吸附无细胞百白破联合疫苗，公司上述已上市的疫苗产品中没有流感疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900006808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300142","BK0077","159646","BK0070","BK0239"],"gpt_icon":0},{"id":"2604167447","title":"沃森生物：已借助AI技术支持研发业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2604167447","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604167447?lang=zh_cn&edition=full","pubTime":"2026-01-20 15:32","pubTimestamp":1768894341,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物01月20日在投资者关系平台上答复投资者关心的问题。公司密切关注相关技术的发展和应用，目前已在一定程度上开始借助相关技术支持和推动研发等业务的发展，并将不断探索其在产品研发、生产及商业化中的应用，相关情况请持续关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260120/31956547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300142","BK0070","BK0046","BK0077","BK0239"],"gpt_icon":0},{"id":"2604491139","title":"沃森生物（300142）披露董事会秘书正式履职公告，1月19日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604491139","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604491139?lang=zh_cn&edition=full","pubTime":"2026-01-19 22:13","pubTimestamp":1768831994,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，沃森生物报收于11.95元，较前一交易日下跌1.32%，最新总市值为191.12亿元。公司近日发布公告称，云南沃森生物技术股份有限公司于2025年6月16日聘任严野先生为公司董事会秘书，其任职在取得深圳证券交易所颁发的《上市公司董事会秘书培训证明》后生效。2026年1月19日，公司确认严野先生已取得该证明，正式履行董事会秘书职责，董事长李云春先生不再代行该职务。严野先生的联系方式已公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900035555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0239","BK0046","BK0077","BK0070"],"gpt_icon":0},{"id":"2603899115","title":"沃森生物（300142）披露关于云南证监局责令改正措施的整改报告，1月16日股价下跌3.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603899115","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603899115?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:09","pubTimestamp":1768572559,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，沃森生物报收于12.11元，较前一交易日下跌3.35%，最新总市值为193.68亿元。公司近日发布公告称，云南沃森生物技术股份有限公司于2026年1月16日召开第五届董事会第三十六次会议，审议通过《关于云南证监局对公司采取责令改正措施决定的整改报告》的议案。公告显示，公司于2025年12月18日收到云南证监局出具的责令改正措施决定，董事会已制定整改方案，明确责任人和整改期限，并将严格落实整改措施，确保合规运作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600040819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","300142","BK0077","BK0239"],"gpt_icon":0},{"id":"2601360120","title":"沃森生物（300142）披露拟换届董事会人选，1月8日股价上涨1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360120","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601360120?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:17","pubTimestamp":1767881834,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，沃森生物报收于11.43元，较前一交易日上涨1.33%，最新总市值为182.81亿元。该股当日开盘11.28元，最高11.47元，最低11.24元，成交额达3.06亿元，换手率为1.73%。近日，沃森生物发布公告称，公司将于2026年1月27日召开2026年第一次临时股东会，会议将审议关于公司董事会换届暨选举第六届董事会非独立董事和独立董事的议案。公告显示，本次会议拟提名4名非独立董事候选人和4名独立董事候选人，选举将采用累积投票制进行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800038874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0070","300142","BK0077"],"gpt_icon":0},{"id":"2600502062","title":"每周股票复盘：沃森生物（300142）拟每10股派0.30元现金","url":"https://stock-news.laohu8.com/highlight/detail?id=2600502062","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600502062?lang=zh_cn&edition=full","pubTime":"2026-01-03 01:59","pubTimestamp":1767376748,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，沃森生物报收于10.91元，较上周的11.3元下跌3.45%。本周，沃森生物12月29日盘中最高价报11.31元。12月31日盘中最低价报10.88元。本周关注点公司公告汇总：沃森生物拟每10股派0.30元现金（含税），股权登记日为2026年1月8日。公司公告汇总云南沃森生物技术股份有限公司2025年半年度权益分派方案已获股东大会审议通过，以总股本1,599,348,541股为基数，向全体股东每10股派0.30元现金（含税），不送红股，不以资本公积金转增股本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","BK0070","300142","BK0239"],"gpt_icon":0},{"id":"2595722707","title":"沃森生物（300142）披露2025年半年度权益分派实施公告，12月31日股价下跌1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595722707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595722707?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:06","pubTimestamp":1767189984,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，沃森生物报收于10.91元，较前一交易日下跌1.45%，最新总市值为174.49亿元。该股当日开盘11.07元，最高11.1元，最低10.88元，成交额达2.06亿元，换手率为1.21%。近日，沃森生物发布2025年半年度权益分派实施公告。根据公告，公司2025年半年度权益分派方案已获股东大会审议通过，以总股本1,599,348,541股为基数，向全体股东每10股派0.30元现金（含税），不送红股，不以资本公积金转增股本。本次权益分派不会导致总股本变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0070","BK0077","300142"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772224185174,"stockEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.0521},{"period":"3month","weight":0.0191},{"period":"6month","weight":-0.0196},{"period":"1year","weight":0.0185},{"period":"ytd","weight":0.1358}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"114040人(较上一季度减少2.75%)","perCapita":"13643股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是人用疫苗。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}